Decibel Therapeutics, Inc. Common Stock (DBTX)

Etorro trading 970x250

About Decibel Therapeutics, Inc. Common Stock

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company’s lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin, or OTOF, gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy, or BVP, by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was founded in 2013 and is based in Boston, Massachusetts. Address: 1325 Boylston Street, Boston, MA, United States, 02215

Decibel Therapeutics, Inc. Common Stock News and around…

Latest news about Decibel Therapeutics, Inc. Common Stock (DBTX) common stock and company :

Decibel Therapeutics to Present at the H.C. Wainwright BioConnect Conference
04 Jan, 2022 Yahoo! Finance

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the H.C. Wainwright BioConnect Conference. The fireside chat will be available for on-demand viewing starting Monday, January 10, 2022 at 7:00 am ET. A we

RSI Alert: Decibel Therapeutics (DBTX) Now Oversold
23 Dec, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Decibel Therapeutics Announces Appointments of Alison Finger, MBA and Saraswathy Nochur, Ph.D. to its Board of Directors; Christine Poon Steps Down from Board
06 Dec, 2021 Yahoo! Finance

BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointments of Alison Finger, MBA and Saraswathy (“Sara”) Nochur, Ph.D. to its Board of Directors. “I am thrilled to welcome Alison and Sara to the Decibel Board. Both bring a wealth of biopharma experience that is very relevant to Decibel’s trajector

Germany- and Boston-based venture firm raises second fund focused on aging
01 Dec, 2021 Yahoo! Finance

Apollo Health Ventures, a venture capital firm based in Berlin, Germany and Boston, has closed its second fund at $180 million (157.5 million euros) to create and invest in companies focused on aging-related diseases.

The Petri Dish: $2.5M for another Bob Langer startup, Decibel extends Regeneron deal
24 Nov, 2021 Yahoo! Finance

While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of Greater Boston life sciences and health care happenings.

Regeneron Extends Hearing Loss Gene Therapy pact With Decibel
22 Nov, 2021 FinancialContent

Regeneron Pharmaceuticals Inc(NASDAQ: REGN) hasextended the research term of its collaborationwithDecibel ...

Decibel Therapeutics Announces Extension of Research Term under Strategic Collaboration with Regeneron to Discover and Develop Gene Therapies for Hearing Loss
22 Nov, 2021 Yahoo! Finance

Collaboration gene therapy product candidate, DB-OTO, on track to enter clinical testing in 2022; two additional gene therapy programs for congenital, monogenic forms of hearing loss in development under the collaborationDecibel to receive $10 million extension payment from Regeneron BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing

Decibel Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update
10 Nov, 2021 Yahoo! Finance

- Received Orphan Drug and Rare Pediatric Disease designations for DB-OTO for the treatment of otoferlin-related congenital hearing loss – - On track for key 2022 milestones including submission of IND and/or CTA for DB-OTO and interim analysis of DB-020 Phase 1b trial for cisplatin-induced hearing loss – - Announces AAV.104 gene therapy program for restoration of hearing in patients with congenital hearing impairment due to recessive mutations in the stereocilin gene – BOSTON, Nov. 10, 2021 (GL

Decibel Therapeutics to Present at the Barclays Gene Editing & Gene Therapy Summit
08 Nov, 2021 Yahoo! Finance

BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced its participation in the fifth annual Barclays Gene Editing & Gene Therapy Summit on Monday, November 15, 2021. Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at 3:30 pm ET and in a panel discussion titled “Ad

3 ‘Strong Buy’ Small-Cap Stocks With Plenty of Upside
28 Oct, 2021 Yahoo! Finance

Investors want to see a return on investment, it’s as simple as that. Regardless of the size of the investment, the end goal remains the same. Sure, there are several ways to go about achieving this objective, yet some Wall Street observers believe that the highest upside potential – and the best place to look for the big returns on investment – is found in the small-cap category. These are stocks valued at less than $2 billion in total market cap, and they typically (but not always) come along

Decibel Therapeutics to Present at the Jefferies Gene Therapy/Editing Summit
20 Oct, 2021 Yahoo! Finance

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 10:30 am ET. A live webcast of the fireside chat may be accessed by visiting t

Scientist behind Vertex CF drugs launches new startup with Atlas Venture
14 Oct, 2021 Yahoo! Finance

Jonathan Moore, one of the first employees of Vertex Pharmaceuticals Inc. and a key scientist behind the company's renowned cystic fibrosis drugs, has a new venture called Rectify Pharmaceuticals.

Decibel Therapeutics Announces Publication of Foundational Study of Noise-related Inner Ear Damage
30 Sep, 2021 FinancialContent
Decibel Therapeutics' Hearing Loss Gene Therapy Receives FDA Orphan Drug Tag
09 Sep, 2021 FinancialContent

TheFDA has granted both Orphan Drug Designation and Rare Pediatric Disease DesignationtoDecibel Therapeutics ...

Decibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Otoferlin-Related Congenital Hearing Loss
09 Sep, 2021 FinancialContent
Decibel Therapeutics to Present at Upcoming Investor Conferences
02 Sep, 2021 FinancialContent
Decibel Therapeutics Appoints Cynthia Hu as Chief Legal Officer and Corporate Secretary
18 Aug, 2021 FinancialContent
Decibel Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
10 Aug, 2021 FinancialContent
12 Health Care Stocks Moving In Friday's Intraday Session
02 Jul, 2021 FinancialContent

Gainers Alector (NASDAQ:ALEC) shares moved upwards by 52.47% to $34.17 during Friday's regular session. ...

12 Health Care Stocks Moving In Thursday's Intraday Session
03 Jun, 2021 FinancialContent

Gainers Kindred Biosciences (NASDAQ:KIN) shares increased by 24.08% to $6.75 during Thursday's regular session. ...

Decibel Therapeutics Appoints Dr. William H. Carson as Chairman of the Board of Directors
02 Jun, 2021 FinancialContent

Distinguished biopharma executive brings over 20 years of leadership in life sciences

The Math Shows IWO Can Go To $371
02 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 2000 Growth ETF (IWO), we found that the implied analyst target price for the ETF based upon its underlying holdings is $370.94 per unit.

Decibel Therapeutics Expands World-Class Scientific Advisory Board
24 May, 2021 FinancialContent

Adds leaders with expertise in hearing loss and balance disorders, combined with experience in gene therapy development

60 Biggest Movers From Yesterday
21 May, 2021 FinancialContent

Gainers Big Rock Partners Acquisition Corp. (NASDAQ: BRPA) shares jumped 88% to settle at $36.08 on Thursday. Urban One, Inc. ...

Decibel Therapeutics to Present at the UBS Global Healthcare Virtual Conference
19 May, 2021 FinancialContent
Decibel Therapeutics Enters Oversold Territory (DBTX)
17 May, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
14 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Decibel Therapeutics Reports First Quarter 2021 Financial Results and Corporate Update
13 May, 2021 FinancialContent
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
11 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
07 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Decibel Therapeutics, Inc. Common Stock (DBTX) is a NASDAQ Common Stock listed in , ,

970x250